Efficacy of Intranasal Esketamine in Treatment-Resistant Depression: A Six-Month Real-World Follow-Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk.
Human psychopharmacology July 1, 2025 Maurizio Pompili, Maria Anna Trocchia, Ludovica Longhini et al. 3 citations
In a real-world outpatient setting, 21 patients with treatment-resistant depression received intranasal esketamine. Depressive symptoms, measured by clinician and self-report scales, decreased at 3-month and 6-month follow-ups. Suicidal ideation significantly declined between baseline and 6 months, and patients also reported reduced hopelessness over time. The findings suggest intranasal esketamine is associated with improvements in depressive symptoms, hopelessness, and suicidal ideation in treatment-resistant depression.